Status:

COMPLETED

Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors

Lead Sponsor:

Sanofi

Conditions:

Cancer

Non-Small Cell Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of XL147 in combination with paclitaxel and carboplatin in adults with solid tumors. XL147 is a new chemical entity that inhibits P...

Eligibility Criteria

Inclusion

  • Confirmed diagnosis of:
  • Advanced solid tumor that is no longer responding to therapies OR
  • Advanced or recurrent endometrial carcinoma OR
  • Advanced or recurrent ovarian carcinoma OR
  • Unresectable (Stage IIIB or IV) NSCLC
  • ECOG Performance Status 0-1 (ECOG status of 2 may be considered following discussion and agreement with sponsor)
  • Adequate organ and bone marrow function as defined by hematological and serum chemistry limits
  • At least 18 years old
  • Both men and women must practice adequate contraception
  • Informed consent

Exclusion

  • Restriction of some therapies/medications within specific timeframes prior to enrollment and during the study including prior therapy with PI3K, AKT, or mTOR inhibitors, cytotoxic chemotherapy, biologic agents, nitrosoureas or mitomycin C, small-molecule kinase inhibitors, non-cytotoxic hormonal agents
  • Known allergy or hypersensitivity to any of the components of the treatment formulations
  • Taking oral corticosteroids chronically or \> 1 mg/day warfarin
  • Not recovered from the toxic effects of prior therapy
  • History of diabetes mellitus.
  • Uncontrolled intercurrent illness
  • Pregnant or breastfeeding
  • Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study.
  • HIV positive
  • Diagnosis of another malignancy may exclude subject from study

Key Trial Info

Start Date :

September 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2012

Estimated Enrollment :

52 Patients enrolled

Trial Details

Trial ID

NCT00756847

Start Date

September 1 2008

End Date

October 1 2012

Last Update

April 10 2013

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Investigational Site Number

St Louis, Missouri, United States, 63110

2

Investigational Site Number

Oklahoma City, Oklahoma, United States, 73104

3

Investigational Site Number

Houston, Texas, United States, 77030-4009

4

Investigational Site Number

Madison, Wisconsin, United States, 53792-6164

Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors | DecenTrialz